EGFR and non-small cell lung carcinoma: As shown in the forest plot (Fig. 4), in patients with stage IIA–IIIA NSCLC, DFS was significantly prolonged in the EGFR-TKI group compared with the control group (HR 0.45, 95% CI 0.27–0.74; P = 0.002).